Zielgerichtete Therapien bei hämatologischen Erkrankungen (Q58023753)

2

0 references

L.-O. Mügge

3

0 references

H.G. Sayer

4

0 references

S. Scholl

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

5

0 references

publication date

20 September 2013

0 references

volume

19

0 references

issue

10

0 references

page(s)

835-847

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Targeting T cells to tumor cells using bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Chronische myeloische Leukämie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Targeted therapy: old and new possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Pathogenesis of Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Hematopoietic SCT in Europe: data and trends in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00761-013-2497-X